alimera-sciences-inc-logo.jpg
Recent 24-Month Real-World PALADIN Data Demonstrate the Ability of ILUVIEN® to Significantly Reduce Treatment Burden in Patients with Diabetic Macular Edema
October 13, 2021 08:00 ET | Alimera Sciences, Inc.
PALADIN Study Data Presented at the American Society of Retina Specialists Shows That Post-ILUVIEN, the Percentage of Eyes Receiving One Yearly Treatment or Less Increased 3.2-Fold Compared to...
alimera-sciences-inc-logo.jpg
Alimera Sciences, Inc. to Present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference
September 02, 2021 16:30 ET | Alimera Sciences, Inc.
ATLANTA, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to...
alimera-sciences-inc-logo.jpg
Alimera Sciences Announces National Pricing and Reimbursement Granted for ILUVIEN® for DME in Belgium
August 24, 2021 08:00 ET | Alimera Sciences, Inc.
ATLANTA, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the commercialization and development of prescription...
alimera-sciences-inc-logo.jpg
Alimera Sciences Announces Second Quarter 2021 Financial Results
August 13, 2021 08:00 ET | Alimera Sciences, Inc.
Consolidated Net Revenue of $21.7 Million up 117% vs. Second Quarter of 2020Consolidated Net Product Revenue of $10.7 Million up 7% vs. Second Quarter of 2020Net Income of $7.6 Million vs. Net Loss of...
alimera-sciences-inc-logo.jpg
Alimera Sciences to Report Second Quarter 2021 Financial Results on Friday, August 13, 2021, and Provide Corporate Update
August 10, 2021 08:00 ET | Alimera Sciences, Inc.
ATLANTA, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera) a global pharmaceutical company that specializes in the commercialization and development of prescription...
alimera-sciences-inc-logo.jpg
Alimera Sciences and Tanner Pharma Group Initiate Global Named Patient Program for ILUVIEN®
August 09, 2021 08:00 ET | Alimera Sciences, Inc.
ATLANTA, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences Europe Limited (“Alimera”), a wholly owned subsidiary of Alimera Sciences, Inc., and Tanner Pharma UK Limited (“Tanner”) announced today...
alimera-sciences-inc-logo.jpg
Alimera Sciences, Inc. to Present at the Summer Solstice – Best Ideas from the Buy Side Conference on June 2, 2021
May 27, 2021 08:15 ET | Alimera Sciences, Inc.
ATLANTA, May 27, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a pharmaceutical company that specializes in the commercialization and development of prescription...
alimera-sciences-inc-logo.jpg
Alimera Sciences Appoints David Dyer, M.D. as Chief Retina Specialist
May 17, 2021 08:12 ET | Alimera Sciences, Inc.
ATLANTA, May 17, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, has announced...
alimera-sciences-inc-logo.jpg
Alimera Sciences Announces First Quarter 2021 Financial Results
April 28, 2021 16:32 ET | Alimera Sciences, Inc.
ATLANTA, April 28, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company that specializes in the commercialization and development of prescription...
alimera-sciences-inc-logo.jpg
Alimera Sciences to Report First Quarter 2021 Financial Results on Wednesday, April 28, 2021 and Provide Corporate Update
April 22, 2021 08:00 ET | Alimera Sciences, Inc.
ATLANTA, April 22, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera) a global pharmaceutical company that specializes in the commercialization and development of prescription...